Oxford Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Oxford Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-16,800	Closed	-$45K	–	2015
2019 Q2	$45K	Buy	+16,800	New	+$60.5K	﹤0.01%	1640
2018 Q2	–	Sell	-53,727	Closed	-$277K	–	1990
2018 Q1	$277K	Sell	53,727 -161,874	-75%	-$1.15M	0.01%	1424
2017 Q4	$834K	Buy	+215,601	New	+$562K	0.02%	1006
2016 Q1	–	Sell	-26,699	Closed	-$244K	–	928
2015 Q4	$244K	Buy	+26,699	New	+$225K	0.01%	775

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Oxford Asset Management's SRNE Position: Q3 2019 in Review

Oxford Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2019, closing a stake of 16,800 shares — an estimated $45K sold.

Oxford Asset Management first reported a position in SRNE in Q4 2015 and held it in 4 quarters. The position peaked at $834K in Q4 2017. 85 funds tracked by Wall St. Rank hold SRNE as of Q3 2019.

Oxford Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Oxford Asset Management sold 16,800 Sorrento Therapeutics, Inc. shares in Q3 2019, an estimated $45K.
Oxford Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2015 and held it in 4 quarters.
Oxford Asset Management's Sorrento Therapeutics, Inc. position peaked at $834K in Q4 2017.
85 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2019.

Based on Oxford Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.